Study on Intraocular Pressure After Aflibercept 0.07mL Injection
The AFLIPIO study will evaluate the intraocular pressure effects and anatomical repercussions of Aflibercept 0.07mL injections over 12 months.
Company
Pharmaceutical intelligence for Anti-VEGF with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.